Skip to content

Comparative Study on Efficacy of Intramuscular Pentazocine/Rectal Diclofenac and Intravenous Infusion Paracetamol/Rectal Diclofenac for Post Caesarean Section Analgesia In University of Calabar Teaching Hospital, Calabar: A Randomized Controlled Trial

Comparative Study on Efficacy of Intramuscular Pentazocine/Rectal Diclofenac and Intravenous Infusion Paracetamol/Rectal Diclofenac for Post Caesarean Section Analgesia In University of Calabar Teaching Hospital, Calabar: A Randomized Controlled Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202501871554044
Enrollment
116
Registered
2025-01-17
Start date
2024-08-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

POST CAESAREAN SECTION ANALGESIA

Interventions

GROUP A
GROUP B

Sponsors

DR. EDIMA MICHAEL OLORY
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: The inclusion criteria will be 1. consenting pregnant women who will undergo either emergency or elective CS under spinal or general anaesthesia who will not be affected by the exclusion criteria during the period of study.

Exclusion criteria

Exclusion criteria: The exclusion criteria will be: 1. Allergy to Pentazocine or Diclofenac or Paracetamol, 2. Peptic ulcer disease, 3. Asthma, 4.Bleeding disorders, 5. History of any cardiovascular, liver, renal disease or present, 6. Past personal or family history of irrational behaviour or known psychiatric illness, 7. Known sickle cell anaemia, 8. Unconscious patients, 9. Eclamptic and 10. Seizure disorder patients, 11. Pre-existing opioid dependency, 12. Intra-uterine fetal death and d 13. Decline consent despite adequate counselling.

Design outcomes

Primary

MeasureTime frame
The primary outcome will be the efficacy of the drug to provide adequate analgesia by the change in the VAS pain intensity score after administration of the drug. The secondary outcome will be patients’ satisfaction.

Secondary

MeasureTime frame
The secondary outcome will be patients’ satisfaction.

Countries

Nigeria

Contacts

Public ContactEDIMA OLORY

NIGERIAN ASSOCIATION OF RESIDENT DOCTORS

edimamichaelolory@gmail.com07038597841

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026